PSA: How to Interpret Your Result

What PSA Actually Measures

PSA is a serine protease enzyme produced almost exclusively by prostatic epithelial cells, and its job is to liquefy semen after ejaculation. A small amount enters the bloodstream. The blood test reports this circulating fraction in nanograms per milliliter (ng/mL). Elevated levels can reflect cancer, but they also rise with benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, urinary tract instrumentation, and even prolonged cycling. The American Cancer Society notes that roughly 75% of men who undergo biopsy for an elevated PSA do not have cancer [1].

That disconnect between an abnormal number and actual disease is the reason interpretation matters more than the raw value. A PSA of 5.2 ng/mL in a 75-year-old man with a 90-gram prostate carries a different clinical weight than the same number in a 48-year-old with a 30-gram gland.

The "Normal" Range and Why It Is Misleading

The traditional threshold of 4.0 ng/mL was established in the late 1980s based on assay calibration, not on cancer biology. It stuck. The Prostate Cancer Prevention Trial (PCPT, N=2,950 men biopsied with PSA <4.0) found that 15.2% of men with a PSA below 4.0 still harbored prostate cancer, and 14.9% of those cancers were high-grade (Gleason 7 or above) [2]. There is no PSA value below which cancer risk drops to zero.

Age-adjusted reference ranges attempt to improve specificity. The ranges proposed by Oesterling et al. and endorsed by several large reference laboratories are [3]:

| Age range | Upper limit of normal | |---|---| | 40-49 | 2.5 ng/mL | | 50-59 | 3.5 ng/mL | | 60-69 | 4.5 ng/mL | | 70-79 | 6.5 ng/mL |

These cutoffs increase detection in younger men (where catching aggressive cancer early has the most benefit) and reduce unnecessary biopsies in older men (where slow-growing tumors often never become clinically significant).

Free PSA Ratio: Refining a Gray-Zone Result

Total PSA between 4.0 and 10.0 ng/mL is sometimes called the "gray zone" because cancer probability sits between roughly 25% and 35%. Free PSA ratio helps distinguish BPH from cancer within that range. PSA circulates either bound to proteins or unbound ("free"). Cancer cells tend to release more complexed (bound) PSA, so a lower percentage of free PSA raises suspicion.

A study by Catalona et al. (N=773) demonstrated that using a free PSA cutoff of 25% could have avoided 20% of unnecessary biopsies while still detecting 95% of cancers in men with total PSA between 4.0 and 10.0 ng/mL [4]. General interpretation guidelines:

• Free PSA above 25%: lower cancer probability; BPH more likely.
• Free PSA between 10% and 25%: intermediate risk; clinical context and imaging guide next steps.
• Free PSA below 10%: higher cancer probability; biopsy discussion is usually warranted.

Your clinician may also order a PSA density calculation (total PSA divided by prostate volume on ultrasound). A density above 0.15 ng/mL/cc adds further concern [5].

PSA Velocity and Doubling Time

A single PSA snapshot tells you less than a trend line. PSA velocity is the rate of change over time. The landmark analysis by Carter et al. found that a velocity exceeding 0.75 ng/mL per year was associated with a significantly higher risk of prostate cancer diagnosis within 7 to 10 years, even when individual readings remained below 4.0 ng/mL [6].

PSA doubling time becomes relevant after a cancer diagnosis or treatment. A doubling time under 3 months after radical prostatectomy is associated with distant metastatic recurrence rather than local-only recurrence, according to data from Pound et al. (N=1,997 post-prostatectomy patients) [7].

To calculate velocity accurately, you need at least three PSA measurements spread over 18 to 24 months, drawn at the same laboratory using the same assay platform. Switching labs mid-series introduces assay-to-assay variability that can mimic a true rise.

PSA and Testosterone Replacement Therapy

Men starting TRT need a clear baseline and a monitoring plan. The Endocrine Society 2018 clinical practice guideline recommends checking PSA before initiating testosterone, again at 3 to 6 months, and then annually [8].

TRT typically raises PSA by 0.3 to 0.5 ng/mL in the first 12 months. The Testosterone Trials (TTrials) consortium (N=790 men aged 65 and older) observed a modest mean PSA increase of approximately 0.4 ng/mL after 12 months of transdermal testosterone gel, with no increase in prostate cancer incidence versus placebo [9]. A rise above 1.4 ng/mL from baseline within any 12-month period, or a total PSA exceeding 4.0 ng/mL, warrants urological referral per the Endocrine Society guideline [8].

Men already using a 5-alpha reductase inhibitor (finasteride or dutasteride) for hair loss or BPH face a compounding variable. These drugs cut measured PSA by roughly 50% within 6 months. The practical rule: double the reported PSA value before interpreting it. The PCPT's long-term data confirmed that this doubling correction restores the test's sensitivity for cancer detection [10].

What Drives PSA Up (Besides Cancer)

High PSA generates anxiety. Knowing the benign causes can prevent unnecessary panic.

BPH. The most common reason for PSA between 4 and 10 ng/mL. Each gram of hyperplastic tissue contributes approximately 0.3 ng/mL to total PSA [5].

Prostatitis. Acute bacterial prostatitis can spike PSA above 20 ng/mL temporarily. The guideline from the European Association of Urology recommends waiting at least 6 weeks after treating prostatitis before repeating PSA for screening purposes [11].

Recent ejaculation. PSA can rise by 0.5 to 0.8 ng/mL within hours of ejaculation. Most reference protocols recommend abstaining for 48 hours before the blood draw.

Mechanical manipulation. Digital rectal exam causes clinically insignificant PSA elevation in most men, but prostate biopsy, transurethral resection, and catheterization produce meaningful spikes lasting days to weeks.

Age. Even without pathology, PSA increases roughly 3.2% per year in healthy men, reflecting growth in prostate volume over time [3].

What Drives PSA Down

Some men search for ways to lower PSA before a recheck. A few factors genuinely reduce it.

5-alpha reductase inhibitors are the most predictable pharmacologic reducer. Finasteride 5 mg daily decreased PSA by a median 50% at 12 months in the PCPT [10]. Dutasteride produces a similar effect.

Statins have shown a modest PSA-lowering association. A meta-analysis of 15 observational studies found that statin users had a statistically significant but small mean PSA reduction compared with non-users [12]. The clinical significance remains debated.

Obesity lowers PSA through hemodilution. Men with a BMI above 30 have roughly 7% lower measured PSA per 5-unit increase in BMI according to data from the National Health and Nutrition Examination Survey (NHANES) [13]. This is not beneficial. Lower PSA in obese men may mask real disease by pushing values below biopsy thresholds.

Anti-androgen medications (enzalutamide, abiraterone, GnRH agonists) suppress PSA dramatically, but these are cancer treatments, not screening-context drugs.

Screening Guidelines: Who Should Get Tested and When

Screening recommendations vary by organization, and the disagreements are real.

The U.S. Preventive Services Task Force (USPSTF, 2018) recommends that men aged 55 to 69 make an individual, informed decision with their clinician about PSA-based screening (Grade C). For men 70 and older, the USPSTF recommends against routine screening (Grade D) [14]. Dr. Alex Krist, then-chair of the USPSTF, stated: "The science shows a small potential benefit of screening for men 55 to 69, but it also shows real harms. Men deserve to know both sides before deciding."

The American Urological Association (AUA, 2013, reaffirmed 2023) recommends shared decision-making starting at age 55 for average-risk men, with consideration of earlier baseline testing at age 40 to 45 for men at higher risk (Black men and men with a first-degree relative diagnosed with prostate cancer before age 65) [15].

The European Randomised Study of Screening for Prostate Cancer (ERSPC) at 16-year follow-up showed a 20% relative reduction in prostate cancer mortality in the screening arm (rate ratio 0.80, 95% CI 0.72-0.89), with a number needed to invite for screening to prevent one prostate cancer death of 570 [16]. The trade-off: for every death prevented, a substantial number of men received diagnoses that would never have caused symptoms.

Putting Your Result in Context: A Decision Framework

Reading a PSA value in isolation is like reading blood pressure without knowing the patient's age, medications, or renal function. Here is how clinicians layer context onto the number.

PSA below 1.0 ng/mL in a man aged 40-49. This is reassuring. The Malmö Preventive Project followed 21,277 men and found that a PSA below 1.0 at age 44 to 50 predicted a very low risk of clinically significant prostate cancer over 25 years, with a negative predictive value exceeding 98% [17]. These men may safely extend their screening interval to every 5 years.

PSA between 1.0 and 2.5 ng/mL in a man aged 50-59. Annual or biennial monitoring is reasonable. Free PSA ratio and PSA velocity add useful signal at this level.

PSA between 4.0 and 10.0 ng/mL. The gray zone. Free PSA, PSA density, MRI of the prostate (PI-RADS scoring), and clinical risk calculators (such as the PCPT Risk Calculator) all feed into the biopsy decision.

PSA above 10.0 ng/mL. Cancer probability rises to approximately 50% or higher. Urological referral and prostate MRI are standard next steps [15].

PSA above 20.0 ng/mL. Bone scan and cross-sectional imaging are often ordered to evaluate for metastatic disease, depending on Gleason score from biopsy.

Common Mistakes Men Make with PSA Results

Skipping the baseline draw at 40 is the first missed opportunity. Without a reference point, a PSA of 2.8 at age 55 could represent a stable value or a significant rise from 0.9 a decade earlier.

Comparing results across different lab assays introduces noise. PSA immunoassays from different manufacturers can vary by 20% to 25% on the same blood sample. Stick with one laboratory.

Panicking over a single elevated value leads to premature biopsy. The NCCN guideline recommends confirming an elevated result with a repeat draw 6 to 8 weeks later before proceeding to biopsy, assuming no other urgent findings on exam [18].

Ignoring the test entirely is the opposite error. Among men aged 55 to 69, the available evidence supports informed screening as a reasonable choice that can reduce prostate cancer mortality [16].

PSA After Prostate Cancer Treatment

After radical prostatectomy, PSA should fall to undetectable levels (below 0.1 ng/mL in most assays) within 6 weeks. A confirmed PSA above 0.2 ng/mL on two consecutive tests defines biochemical recurrence per the AUA/ASTRO guideline [19].

After radiation therapy, the pattern differs. PSA drops slowly over 12 to 24 months, and the nadir varies. Biochemical recurrence after radiation is defined as a rise of 2.0 ng/mL or more above the post-treatment nadir (the "Phoenix definition") [19].

For men on active surveillance for low-risk prostate cancer (Gleason 3+3, PSA <10, low-volume disease), PSA is checked every 6 months. A PSA doubling time under 3 years or a significant density increase triggers consideration of repeat biopsy or reclassification [18].